SUBSCRIBE
SUBSCRIBE
News   Business

Skyepharma PLC Says Abbott Laboratories Quits Flutiform Partnership

August 20, 2010 | 
1 min read
LONDON, Aug 19 (Reuters) - Britain's SkyePharma (SKP.L) said Abbott Laboratories (ABT.N) has ended its deal to market SkyePharma's asthma drug Flutiform in the United States, after regulators imposed what could be insurmountable hurdles to approval.
Alliances Europe
Abbott Laboratories
MORE ON THIS TOPIC
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Biogen axes ‘small number’ of Apellis roles after $5.6B buy
June 26, 2026
 · 
63 min read
 · 
BioSpace Editorial Staff
Businessmen look at the city from the outskirts.
Pipeline
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
June 26, 2026
 · 
2 min read
 · 
Tristan Manalac
Big fish eats small, takeover of the company. Art collage.
M&A
Merck KGaA inks $11B Bio-Techne buyout to expand into cell therapy production
June 26, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker